Gilead Faces Doubts on Wall Street a Year After $12 Billion Deal

(Bloomberg) -- Investors in Gilead Sciences Inc. are still waiting for the company to prove the value of last year’s purchase of Kite Pharma Inc., and time may be running out.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.